Products and Services » Diagnostics
Prometheus diagnostic services provide important information to help in the diagnosis and treatment of diseases. Test results should be used with other clinical findings to help physicians make a confirmed diagnosis.
Prometheus Laboratories Inc., a leader in gastrointestinal diagnostic testing, is proud to introduce its newest accomplishment in cutting-edge diagnostic services, the PROMETHEUS® Anser™ IFX test. The PROMETHEUS Anser IFX test is a quantitative monitoring assay that allows healthcare providers to measure and monitor serum infliximab and antibodies to infliximab (ATI) levels at anytime during therapy. Incorporating drug monitoring may clarify what factors are contributing to a patient's loss of response and help guide treatment decisions by providing information to help determine an appropriate course of action.
The new Prometheus IBD sgi Diagnostic is the 4th-generation IBD diagnostic test and the first and only test to combine serologic, genetic, and inflammation markers in the proprietary Smart Diagnostic Algorithm for added diagnostic clairty. This test will aid healthcare providers in differentiating IBD vs non-IBD, and CD vs UC, in one comprehensive blood test.
PROMETHEUS® Celiac Genetics is a test that analyzes your genetic profile for certain genes (HLA DQ2 and HLA DQ8) associated with celiac disease. The result can predict with a 95%-100% chance that you do not have celiac disease. It could also show that you are very unlikely to ever develop the disease. Alternatively, the results may show that you do have genes associated with celiac disease and that you are at increased risk of developing symptoms, even if your serology (antibody) test is negative.
PROMETHEUS® Celiac Serology is a test to measure specific antibody levels in your body that are associated with active celiac disease. If the levels are high, celiac disease is likely. For patients with celiac disease, these antibody levels should drop over time once patients remove gluten from their diet. This test may help your physician to diagnose celiac disease and monitor your compliance to a gluten-free diet.
PROMETHEUS® Thiopurine Metabolites is a test to monitor thiopurine medications. Because everyone metabolizes medications differently, your doctor may order this test to make sure your level of treatment is within a range that may help control symptoms.
PROMETHEUS® TPMT Genetics is a test to determine the presence of genetic mutations associated with a decreased production of the thiopurine methyltransferase (TPMT) enzyme. This enzyme is responsible for the metabolism of a class of thiopurine drugs. Knowing the TPMT genotype allows your physician to individualize your dosing, and help identify patients who should not take these medications.
PROMETHEUS® TPMT Enzyme is a test to determine the amount of thiopurine methyltransferase (TPMT) enzyme in your red blood cells. This enzyme is responsible for the metabolism of a class of thiopurine drugs. Knowing the TPMT enzyme levels allows your physician to individualize your dosing, and helps identify patients who should not take these medications.
PROMETHEUS® FIBROSpect® II is a test for patients diagnosed with hepatitis C who are at risk for developing liver fibrosis. This test uses a combination of protein markers to help predict the presence or absence of liver fibrosis and/or cirrhosis. This test is useful for initial patient evaluations and may help reduce the number of liver biopsies.
PROMETHEUS® LactoTYPE® is a test used to identify a genetic variant that is strongly associated with the reduced production of lactase in adults. Lactase is an enzyme necessary for the digestion of the sugar lactose found in dairy products. Patients with this genetic variant typically have sensitivity to dairy products and are often diagnosed with lactose intolerance. Alternatively, patients with diagnosed lactose intolerance who do not have this genetic variant may have other underlying causes for their symptoms.
PROMETHEUS® NOD2/CARD15 is a test to evaluate certain genetic variants for patients diagnosed with Crohn’s disease. Detection of one or more NOD2/CARD15 genetic mutations suggests a risk of having more severe symptoms and complications of the disease. This test is used to help establish a prognosis that may help guide treatment decisions by you and your doctor.
Medical Information & Adverse Events for: LOTRONEX® (alosetron hydrochloride), Helidac® (bismuth subsalicylate/ metronidazole/ tetracycline/ hydrochloride), Imuran® (azathioprine), Ridura® (auranofin), Trandate® (labetalol hydrochloride), Zyloprim® (allopurinol), and Mercaptopurine - Call directly to (888) 423-5227 Opt. # 6.